The cost-effectiveness of expanding the NHS newborn bloodspot screening programme to include homocystinuria (HCU), maple syrup urine disease (MSUD), glutaric aciduria type 1 (GA1), isovaleric acidaemia (IVA), and long-chain hydroxyl acyl-CoA dehydrogenase deficiency (LCHADD) (2014)
The NHS newborn bloodspot screening programme screens all babies in England for five rare conditions. This study assessed the economics of expanding the screening programme to include five new inborn errors of the metabolism; HCU, MSUD, GA1, IVA, and LCHADD.
EthicsThere is no personal data or any that requires ethical approval
PolicyThe data complies with the institution and funders' policies on access and sharing
Sharing and access restrictionsThe data can be shared openly
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files